Rarity Bioscience provides ultrasensitive multiplex assays for detecting rare nucleic acid sequences in biological samples like liquid biopsies for research, pharma and clinic. Our technology platform – Rarity SafeLock – permits read-out based on flow cytometry and already existing instrumentation. The company was founded 2021 based on a discovery by Dr Lei Chen, PhD in molecular biology and a member of Professor Ulf Landegrens team at the Department of Immunology, Genomics and Pathology at Uppsala University.